Atripla - efavirenz, emtricitabine, and tenofovir disoproxil fumarate
Navigation: NDC > Supplier starting with: B > BRISTOL MYERS SQUIBB & GILEAD SCIENCES, LLC| Field | Value |
|---|---|
| NDC Code: | 15584-0101 |
| Proprietary Name: | Atripla |
| Suffix: | |
| Non-Proprietary Name: | efavirenz, emtricitabine, and tenofovir disoproxil fumarate |
| Dosage Form: | TABLET, FILM COATED |
| Method: | ORAL |
| Original Marketing Date: | 20-07-2006 |
| Category Name: | NDA |
| Application Number: | NDA021937 |
| Labeler: | BRISTOL MYERS SQUIBB & GILEAD SCIENCES, LLC |
| Substance Name: | EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE |
| Active Numerator Strength: | 600; 200; 300 |
| Active Ingredient Unit: | mg/1; mg/1; mg/1 |
| Pharm Classes: | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| DEA Schedule: |